Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.96M Sell
48,900
-76,400
-61% -$3.62M ﹤0.01% 4996
2025
Q4
$5.63M Sell
125,300
-85,393
-41% -$3.95M ﹤0.01% 3901
2025
Q3
$9.41M Sell
210,693
-100
-0% -$4.79K ﹤0.01% 3365
2025
Q2
$10.1M Buy
210,793
+85,400
+68% +$3.71M ﹤0.01% 3069
2025
Q1
$5.03M Buy
125,393
+1,629
+1% +$68.5K ﹤0.01% 3764
2024
Q4
$5.67M Buy
+123,764
New +$5.54M ﹤0.01% 3689
2024
Q3
Sell
-233,528
Closed -$9.87M 9954
2024
Q2
$9.87M Buy
233,528
+186,375
+395% +$8.17M ﹤0.01% 2222
2024
Q1
$2.09M Buy
+47,153
New +$2.15M ﹤0.01% 3918
2023
Q1
Sell
-188,611
Closed -$9.97M 10227
2022
Q4
$9.97M Buy
188,611
+75,444
+67% +$3.72M ﹤0.01% 1933
2022
Q3
$4.95M Buy
+113,167
New +$5.59M ﹤0.01% 2353
2021
Q4
Sell
-4,715
Closed -$258K 10606
2021
Q3
$258K Buy
+4,715
New +$263K ﹤0.01% 5140
2021
Q1
Sell
-169,184
Closed -$9.48M 9376
2020
Q4
$9.48M Buy
+169,184
New +$9.03M ﹤0.01% 1892
2020
Q2
Sell
-47,153
Closed -$2.08M 8272
2020
Q1
$2.08M Buy
+47,153
New +$1.84M ﹤0.01% 2722
2019
Q1
Sell
-300,878
Closed -$11M 8068
2018
Q4
$11M Buy
+300,878
New +$11.2M 0.01% 1500

Other funds holding QGEN

UBS Group's QGEN Position: Q1 2026 in Review

UBS Group increased its Qiagen (QGEN) stake by 24% in Q1 2026, buying an estimated $13M and bringing the position to 1,428,307 shares worth $57.2M. The position accounts for 0.01% of the portfolio, ranked #1516.

UBS Group first reported a position in QGEN in Q1 2017 and has held it in 37 quarters since. The position peaked at $215M in Q1 2020. 344 funds tracked by Wall St. Rank hold QGEN as of Q1 2026.

  • UBS Group held 1,428,307 shares of Qiagen worth $57.2M as of Q1 2026.
  • UBS Group bought 274,885 Qiagen shares in Q1 2026, an estimated $13M.
  • Qiagen made up 0.01% of UBS Group's portfolio in Q1 2026, its #1516 holding.
  • UBS Group first reported a position in Qiagen in Q1 2017 and has held it in 37 quarters since.
  • UBS Group's Qiagen position peaked at $215M in Q1 2020.
  • 344 funds tracked by Wall St. Rank held Qiagen as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.